The shadow of generic challenges has long loomed above copyright’s iconic drug, PDE5 Inhibitor, raising questions about the prospects of similar drug portfolios. While initial periods saw significant returns, the exclusivity end has allowed the way for less expensive substitutes, likely lowering earnings and posing a genuine danger for investors